Essential Reads: Zuranolone for Postpartum Depression
In 2019, the Food and Drug Administration (FDA) approved brexanolone, marketed by Sage Therapeutics as Zulresso, as a treatment for postpartum depression (PPD). As a neurosteroid, brexanolone represents a novel approach to the treatment of postpartum mood disorders. One of the most exciting things about brexanolone is the rapidity of the response, with the initial… Read More »